Drug Sponsors

Mylan to acquire Agila to create global injectables platform

Thursday, February 28, 2013 03:19 PM

Pittsburgh-based Mylan has signed a definitive agreement to acquire Agila Specialties Private Limited, a developer, manufacturer and marketer of high-quality generic injectable products, from Strides Arcolab for $1.6 billion in cash.

More... »

Optimer board chairman McKinnell named CEO

Thursday, February 28, 2013 03:09 PM

The board of directors of Jersey City, N.J.-based Optimer Pharmaceuticals has appointed its chairman, Dr. Henry McKinnell, chief executive officer. McKinnell was Pfizer's CEO and chairman from 2001 to 2006 and was with Pfizer from 1971 until his retirement in 2007.

More... »

Roche launches process for accessing clinical trial data

Thursday, February 28, 2013 02:24 PM

Basel, Switzerland-based Roche is expanding access to its clinical trial data for third-party researchers. Roche will work with an independent body of recognized experts to evaluate and approve requests to access anonymized patient-level data.

More... »

Qualicaps to expand N.C. facility, create 123 jobs

Wednesday, February 27, 2013 12:23 PM

Qualicaps, a manufacturer of gelatin capsules and wholly owned subsidiary of Qualicaps Group, plans to expand its facility in Whitsett, N.C.

More... »

Intersect ENT raises $30M in Series D financing

Wednesday, February 27, 2013 10:58 AM

Intersect ENT, a Menlo Park, Calif.-based innovator in treatment solutions for ear, nose and throat clinicians and their patients, has completed the initial closing of a $30 million Series D round of funding. The financing will be used to continue the rapid commercial expansion in the U.S. for the company's PROPEL and PROPEL mini sinus implants and to fund clinical studies of the company's latest product, an office-based treatment for chronic sinusitis sufferers.

More... »

Sapiens attracts $9.8M for next generation deep brain stimulation therapy

Wednesday, February 27, 2013 10:01 AM

Sapiens Steering Brain Stimulation, an emerging medical technology company developing brain stimulation products, has raised $9.8 million from the Dutch investment group INKEF Capital, in a further extension of their Series A financing round. The proceeds will be used for the development of its Steering Brain Stimulation implant and procedure solutions to treat Parkinson's disease (PD) and other functional brain disorders.

More... »

Elan acknowledges Royalty’s proposal

Monday, February 25, 2013 10:57 AM

The board of Elan, a biotechnology company based in Ireland, has acknowledged the announcement by Royalty Management regarding an indicative, conditional, proposal which may or may not lead to an offer being made for the entire issued share capital of Elan.

More... »

Blaze Bioscience raises $9.8M in Series A financing

Monday, February 25, 2013 10:28 AM

Blaze Bioscience, a Seattle-based biotechnology company focused on cancer, has completed a Series A financing totaling $8.5 million, bringing the total funds raised since inception to $9.8 million.

More... »

Ambit Biosciences registers for proposed IPO

Friday, February 22, 2013 10:47 AM

Ambit Biosciences, a privately held biopharmaceutical company, has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for an initial public offering of its common stock on the NASDAQ stock market.

More... »

Aerial Biopharma closes second tranche of Series A for narcolepsy drug

Wednesday, February 20, 2013 03:19 PM

Aerial BioPharma, a privately held biopharmaceutical company based in Morrisville, N.C., has completed the second tranche of its $12 million dollar Series A financing.  The company has now raised $9.5 million, with the third and final tranche of the Series A to be completed in the fourth quarter of 2013. 

More... »